Arachidonic acid metabolism as a therapeutic target in AKI-to-CKD transition.
acute kidney injury
arachidonic acid
chronic kidney disease
inflammation
oxidative stress
renal cell carcinoma
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2024
2024
Historique:
received:
05
01
2024
accepted:
06
02
2024
medline:
25
3
2024
pubmed:
25
3
2024
entrez:
25
3
2024
Statut:
epublish
Résumé
Arachidonic acid (AA) is a main component of cell membrane lipids. AA is mainly metabolized by three enzymes: cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 (CYP450). Esterified AA is hydrolysed by phospholipase A
Identifiants
pubmed: 38523633
doi: 10.3389/fphar.2024.1365802
pii: 1365802
pmc: PMC10957658
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1365802Informations de copyright
Copyright © 2024 Li, Suo, Wang, Zou, Nie, Zhao and Miao.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.